Max Meyrath
Latest publications
Atypical opioid receptors: unconventional biology and therapeutic opportunities.
- Immuno-Pharmacology and Interactomics
2021 Oct. Pharmacol Ther.108014. Online ahead of print.
New insights into the atypical chemokine receptor network and functions. (Doctoral thesis)
- Immuno-Pharmacology and Interactomics
2021 Jul. Liège: Université de Liège, 2021.
The natural analgesic conolidine targets the newly identified opioid scavenger ACKR3/CXCR7.
- Immuno-Pharmacology and Interactomics
2021 Jun. Signal Transduct Target Ther.6(1):209.
Proadrenomedullin N-Terminal 20 Peptides (PAMPs) are agonists of the chemokine scavenger receptor ACKR3/CXCR7.
- Immuno-Pharmacology and Interactomics
- Allergy and Clinical Immunology
2021 Apr. ACS Pharmacol Transl Sci.4(2):813-823.
CXCL10 Is an Agonist of the CC Family Chemokine Scavenger Receptor ACKR2/D6.
- Immuno-Pharmacology and Interactomics
- Tumor Immunotherapy and Microenvironment
- Allergy and Clinical Immunology
- Personalized Therapy Discovery
2021 Mar. Cancers.13(5):1054.
Systematic reassessment of chemokine-receptor pairings confirms CCL20 but not CXCL13 and extends the spectrum of ACKR4 agonists to CCL22.
- Immuno-Pharmacology and Interactomics
2021 Feb. J Leukoc Biol.109(2):373-376. Epub 2020 Jun 1.
CXCL14 Preferentially Synergizes With Homeostatic Chemokine Receptor Systems.
- Immuno-Pharmacology and Interactomics
2020 Oct. Front Immunol.11:561404.
The atypical chemokine receptor ACKR3/CXCR7 is a broad-spectrum scavenger for opioid peptides.
- Immuno-Pharmacology and Interactomics
- Immune Endocrine and Epigenetics
- Transversal Translational Medicine
- Allergy and Clinical Immunology
2020 Jun. Nat Commun.11(1):3033.
Assessment of biased agonism among distinct synthetic cannabinoid receptor agonist scaffolds.
- Immuno-Pharmacology and Interactomics
2020 Apr. ACS Pharmacol Transl Sci.3(2):285-295.
The diverse and complex roles of atypical chemokine receptors in cancer: From molecular biology to clinical relevance and therapy.
- Immuno-Pharmacology and Interactomics
2020 Feb. Adv Cancer Res.145:99-138. Epub 2020 Feb 14.
The soluble form of pan-RTK inhibitor and tumor suppressor LRIG1 mediates downregulation of AXL through direct protein-protein interaction in glioblastoma.
- NORLUX Neuro-Oncology Laboratory
- Multiomics Data Science
- Immuno-Pharmacology and Interactomics
2019 Sep. Neurooncol Adv.1(1):vdz024.
A novel ACKR2-dependent role of fibroblast-derived CXCL14 in epithelial-to-mesenchymal transition and metastasis of breast cancer.
- Immuno-Pharmacology and Interactomics
2019 Jun. Clin Cancer Res.25(12):3702-3717. Epub 2019 Mar 8.
Mutational analysis of the extracellular disulphide bridges of the atypical chemokine receptor ACKR3/CXCR7 uncovers multiple binding and activation modes for its chemokine and endogenous non-chemokine agonists.
- Immuno-Pharmacology and Interactomics
2018 Jul. Biochem Pharmacol.153:299-309. Epub 2018 Mar 9.
Different contributions of chemokine N-terminal features attest to a different ligand binding mode and a bias towards activation of ACKR3/CXCR7 compared with CXCR4 and CXCR3.
- Immuno-Pharmacology and Interactomics
2018 May. Br J Pharmacol.175(9):1419-1438. Epub 2018 Mar 23.